BRAF and melanoma: This study confirmed the co-occurrence of BRAF mutation with IDH1 mutation previously observed, and demonstrated that mutant IDH1 conferred in a BRAF V600E melanoma cell line acquired in vivo growth activities and enhanced activation of the MAPK and STAT3 pathways (Lopez et al., 2010; Shibata et al., 2011).